Rain Therapeutics to Participate in the 41st Annual J.P. Morgan Health Care Conference
Rain Therapeutics Inc. (NasdaqGS: RAIN) announced its participation in the J.P. Morgan 41st Annual Health Care Conference from January 9-12, 2023, in San Francisco, CA. CEO Avanish Vellanki will present on January 11, 2023, at 9:00 a.m. PT, offering a corporate overview. Rain is a late-stage biotechnology firm focusing on precision oncology therapeutics, notably its lead candidate, milademetan, an oral inhibitor of the MDM2-p53 complex, designed to reactivate p53.
The company utilizes a tumor-agnostic strategy to identify patients likely to benefit from its therapies.
- None.
- None.
NEWARK, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in J.P. Morgan’s 41st Annual Health Care Conference, being held January 9 – 12, 2023, in San Francisco, CA.
Avanish Vellanki, chief executive officer of Rain, will be presenting a corporate overview on Wednesday, January 11, 2023 at 9:00 a.m. PT. An audio of the presentation can be accessed here. The Company’s management team will participate in one-on-one investor meetings.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
FAQ
When is Rain Therapeutics presenting at the J.P. Morgan Health Care Conference?
What is the focus of Rain Therapeutics' lead product candidate, milademetan?
What type of company is Rain Therapeutics?
What is the significance of the J.P. Morgan Health Care Conference for Rain Therapeutics?
What strategy does Rain Therapeutics use to select patients for its therapies?
